ストックスクリーナーアプリを入手
1.99
1.00%
-0.02
プレマーケット:
1.99
前日終値:
$2.01
開ける：
$2.07
24時間の取引高:
912.33K
Relative Volume:
0.96
時価総額：
$164.09M
収益：
$153.73M
当期純損益:
$-106.79M
株価収益率:
-1.118
EPS:
-1.78
ネットキャッシュフロー:
$-115.93M
1週間 パフォーマンス:
+15.70%
1か月 パフォーマンス:
+5.85%
6か月 パフォーマンス:
-47.14%
1年 パフォーマンス:
-50.99%
1日の値動き範囲:
$1.905
$2.07
1週間の範囲:
$1.72
$2.08
52週間の値動き範囲:
$1.67
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
名前
Sutro Biopharma Inc
セクター
電話
650-392-8412
住所
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
STRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
1.99 | 164.09M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-08 | 開始されました | BofA Securities | Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-06 | 開始されました | Oppenheimer | Outperform |
| 2023-03-21 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2021-06-18 | 開始されました | H.C. Wainwright | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-09-02 | 開始されました | Jefferies | Buy |
| 2020-07-16 | 開始されました | Wells Fargo | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-10-07 | 開始されました | BTIG Research | Buy |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
| 2018-10-22 | 開始されました | Wedbush | Outperform |
すべてを表示
Sutro Biopharma Inc (STRO) 最新ニュース
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Sees Large Growth in Short Interest - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Barclays PLC Acquires 216,757 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $1.7 amid market challenges - Investing.com Nigeria
Sutro Biopharma (NASDAQ:STRO) versus Sorrento Therapeutics (OTCMKTS:SRNEQ) Head-To-Head Comparison - Defense World
Jane Street Group LLC Acquires 25,416 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale - The Manila Times
Sutro Biopharma Achieves Breakthrough: Cell-Free Cancer Drug Production Scales to 4,500L - StockTitan
Great week for Sutro Biopharma, Inc. (NASDAQ:STRO) institutional investors after losing 42% over the previous year - Simply Wall St
Geode Capital Management LLC Has $6.43 Million Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless (NASDAQ:STRO) - Seeking Alpha
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Barclays PLC - Defense World
Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Expands By 19.4% - MarketBeat
State Street Corp Buys 81,855 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $11.13 Consensus PT from Analysts - MarketBeat
Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Charles Schwab Investment Management Inc. Acquires 35,167 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $2.02 By Investing.com - Investing.com Canada
Fmr LLC Acquires 37,701 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $2.02 - Investing.com
BNP Paribas Financial Markets Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Novavax (NASDAQ:NVAX) and Sutro Biopharma (NASDAQ:STRO) Financial Review - Defense World
Sutro Biopharma's SWOT analysis: promising pipeline drives stock outlook - Investing.com
Wells Fargo & Company Lowers Sutro Biopharma (NASDAQ:STRO) Price Target to $4.00 - Defense World
Sutro Biopharma’s (STRO) Outperform Rating Reiterated at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Earns “Market Outperform” Rating from JMP Securities - Defense World
Expert Outlook: Sutro Biopharma Through The Eyes Of 6 Analysts - Benzinga
Sutro Biopharma stock hits 52-week low at $2.45 - Investing.com India
Sutro Biopharma stock hits 52-week low at $2.45 By Investing.com - Investing.com Canada
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer - The Manila Times
Sutro's Luvelta Shows Promising 32% Response Rate in Ovarian Cancer Trial, Eyes FDA Fast Track - StockTitan
Intech Investment Management LLC Makes New Investment in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Point72 Asset Management L.P. Decreases Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Jacobs Levy Equity Management Inc. Lowers Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Bank of Montreal Can Makes New Investment in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma (FRA:S09) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
Sutro Biopharma (FRA:S09) Enterprise Value : €-129.3 Mil (As of Dec. 04, 2024) - GuruFocus.com
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Price Target at $12.14 - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Sees Large Drop in Short Interest - MarketBeat
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge - Simply Wall St
Suvretta Capital Management LLC Sells 521,195 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $12.14 - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $1.51 Million in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma (STU:S09) Enterprise Value : €-142.7 Mil (As of Nov. 27, 2024) - GuruFocus.com
Sutro Biopharma (STU:S09) Forward Dividend Yield % : 0.00% (As of Nov. 27, 2024) - GuruFocus.com
Sutro Biopharma Inc (STRO) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):